Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Janux Therapeutics

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Announces Proposed Public Offering of Common Stock
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Tickers JANX
Janux Therapeutics Appoints Dr. Wayne Godfrey as Chief Medical Officer
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
From Janux Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.